Free Trial

Zoetis (ZTS) Competitors

Zoetis logo
$160.39 +2.97 (+1.89%)
Closing price 02/21/2025 03:59 PM Eastern
Extended Trading
$161.30 +0.91 (+0.56%)
As of 02/21/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ZTS vs. MRK, PFE, BMY, RPRX, JAZZ, CORT, PRGO, SUPN, PCRX, and OMER

Should you be buying Zoetis stock or one of its competitors? The main competitors of Zoetis include Merck & Co., Inc. (MRK), Pfizer (PFE), Bristol-Myers Squibb (BMY), Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ), Corcept Therapeutics (CORT), Perrigo (PRGO), Supernus Pharmaceuticals (SUPN), Pacira BioSciences (PCRX), and Omeros (OMER). These companies are all part of the "pharmaceuticals" industry.

Zoetis vs.

Zoetis (NYSE:ZTS) and Merck & Co., Inc. (NYSE:MRK) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their community ranking, media sentiment, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk.

Zoetis presently has a consensus price target of $214.90, suggesting a potential upside of 33.83%. Merck & Co., Inc. has a consensus price target of $116.39, suggesting a potential upside of 30.62%. Given Zoetis' stronger consensus rating and higher probable upside, equities research analysts plainly believe Zoetis is more favorable than Merck & Co., Inc..

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zoetis
0 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
2 Strong Buy rating(s)
3.08
Merck & Co., Inc.
1 Sell rating(s)
11 Hold rating(s)
9 Buy rating(s)
3 Strong Buy rating(s)
2.58

Merck & Co., Inc. received 81 more outperform votes than Zoetis when rated by MarketBeat users. However, 78.03% of users gave Zoetis an outperform vote while only 66.80% of users gave Merck & Co., Inc. an outperform vote.

CompanyUnderperformOutperform
ZoetisOutperform Votes
913
78.03%
Underperform Votes
257
21.97%
Merck & Co., Inc.Outperform Votes
994
66.80%
Underperform Votes
494
33.20%

Zoetis has a beta of 0.9, meaning that its share price is 10% less volatile than the S&P 500. Comparatively, Merck & Co., Inc. has a beta of 0.38, meaning that its share price is 62% less volatile than the S&P 500.

Zoetis has a net margin of 26.86% compared to Merck & Co., Inc.'s net margin of 26.67%. Zoetis' return on equity of 53.82% beat Merck & Co., Inc.'s return on equity.

Company Net Margins Return on Equity Return on Assets
Zoetis26.86% 53.82% 18.86%
Merck & Co., Inc. 26.67%45.35%17.36%

Merck & Co., Inc. has higher revenue and earnings than Zoetis. Merck & Co., Inc. is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zoetis$9.26B7.77$2.49B$5.4729.36
Merck & Co., Inc.$64.17B3.51$17.12B$6.7313.24

In the previous week, Merck & Co., Inc. had 53 more articles in the media than Zoetis. MarketBeat recorded 118 mentions for Merck & Co., Inc. and 65 mentions for Zoetis. Zoetis' average media sentiment score of 0.99 beat Merck & Co., Inc.'s score of 0.74 indicating that Zoetis is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Zoetis
43 Very Positive mention(s)
3 Positive mention(s)
5 Neutral mention(s)
7 Negative mention(s)
1 Very Negative mention(s)
Positive
Merck & Co., Inc.
71 Very Positive mention(s)
9 Positive mention(s)
30 Neutral mention(s)
3 Negative mention(s)
3 Very Negative mention(s)
Positive

Zoetis pays an annual dividend of $2.00 per share and has a dividend yield of 1.2%. Merck & Co., Inc. pays an annual dividend of $3.24 per share and has a dividend yield of 3.6%. Zoetis pays out 36.6% of its earnings in the form of a dividend. Merck & Co., Inc. pays out 48.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Zoetis has raised its dividend for 14 consecutive years and Merck & Co., Inc. has raised its dividend for 14 consecutive years.

92.8% of Zoetis shares are held by institutional investors. Comparatively, 76.1% of Merck & Co., Inc. shares are held by institutional investors. 0.2% of Zoetis shares are held by insiders. Comparatively, 0.1% of Merck & Co., Inc. shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Zoetis beats Merck & Co., Inc. on 13 of the 20 factors compared between the two stocks.

Get Zoetis News Delivered to You Automatically

Sign up to receive the latest news and ratings for ZTS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ZTS vs. The Competition

MetricZoetisPharmaceutical IndustryMedical SectorNYSE Exchange
Market Cap$71.85B$7.07B$5.80B$20.06B
Dividend Yield1.28%2.87%4.78%3.65%
P/E Ratio29.336.0226.3234.91
Price / Sales7.77316.05452.0815.74
Price / Cash22.1567.8344.0420.85
Price / Book15.086.757.644.93
Net Income$2.49B$138.11M$3.18B$1.02B
7 Day Performance1.93%-1.85%-1.66%-0.92%
1 Month Performance-4.13%-1.39%0.41%-1.26%
1 Year Performance-14.76%-2.92%17.47%14.15%

Zoetis Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ZTS
Zoetis
4.8701 of 5 stars
$160.39
+1.9%
$214.90
+34.0%
-14.9%$71.82B$9.26B29.3214,100
MRK
Merck & Co., Inc.
5 of 5 stars
$83.01
-1.7%
$117.06
+41.0%
-30.2%$209.99B$64.17B12.3372,000Analyst Downgrade
Options Volume
PFE
Pfizer
4.9993 of 5 stars
$25.50
-0.6%
$31.92
+25.2%
-4.9%$144.48B$63.63B18.0888,000Options Volume
Positive News
BMY
Bristol-Myers Squibb
4.6002 of 5 stars
$53.85
-3.8%
$57.86
+7.4%
+9.7%$109.22B$48.30B-12.1834,100Analyst Revision
Positive News
RPRX
Royalty Pharma
4.5507 of 5 stars
$32.36
-0.3%
$41.67
+28.8%
+7.0%$19.07B$2.36B16.7780Positive News
JAZZ
Jazz Pharmaceuticals
4.9543 of 5 stars
$133.96
-2.1%
$180.33
+34.6%
+5.9%$8.10B$3.83B18.872,800Upcoming Earnings
CORT
Corcept Therapeutics
4.6763 of 5 stars
$72.72
-1.2%
$88.25
+21.4%
+193.4%$7.62B$482.38M57.71300Upcoming Earnings
PRGO
Perrigo
4.9746 of 5 stars
$24.48
-1.3%
$35.00
+43.0%
-20.7%$3.34B$4.66B-20.939,140Dividend Increase
Analyst Downgrade
News Coverage
SUPN
Supernus Pharmaceuticals
1.6055 of 5 stars
$39.11
-1.1%
$46.50
+18.9%
+17.4%$2.16B$607.52M36.55580Analyst Downgrade
News Coverage
PCRX
Pacira BioSciences
3.297 of 5 stars
$25.44
-4.1%
$22.78
-10.5%
-15.3%$1.17B$674.98M-12.53720
OMER
Omeros
3.7814 of 5 stars
$9.18
+0.7%
$22.50
+145.1%
+116.5%$531.98MN/A-3.97210Analyst Forecast
News Coverage

Related Companies and Tools


This page (NYSE:ZTS) was last updated on 2/22/2025 by MarketBeat.com Staff
From Our Partners